Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications

NEXT STORY
ADMA Receives Department of Health and Human Services U.S. License
PREV STORY
Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017 and ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech plans a reverse share split

FIT Biotech Oy Company release 24.1.2019 at 09:20 am EET FIT Biotech plans a reverse ...

author_avatar
NASDAQ Market News

Amarin Announces Approval for Vascepa® in United Arab Emirates

Approval is Second Middle East Country to Approve Vascepa Sale Following Lebanon Earlier This ...

author_avatar
NASDAQ Market News